FreeTheAI

Arcutis Biotherapeutics Shares Rise Following Cantor Fitzgerald Coverage Initiation

BullishMedium impact
ARQT$28.82 9.13%

Arcutis Biotherapeutics (ARQT) shares jumped nearly 9% to $28.75, reaching their highest trading level since January. The rally followed research coverage initiation from Cantor Fitzgerald, which assigned an Overweight rating and a $48 price target for the dermatology biotech firm.

The positive outlook centers on commercial momentum for Zoryve, the company's primary topical therapy for inflammatory skin conditions including atopic dermatitis. Accelerating prescription volumes continue to drive market share expansion across the branded topical market.

Looking ahead, investors will monitor whether the business can deliver on its updated full-year financial targets. Following second-quarter earnings, management raised its annual net product sales forecast to between $525 million and $540 million, up from a previous guidance range of $480 million to $495 million.

Key points

  • Cantor Fitzgerald started coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and a $48 price target.
  • Arcutis shares gained 8.88% to $28.75, hitting their highest price since January.
  • Prescription growth for lead product Zoryve is expanding the company's share in the branded topical market.
  • Arcutis previously raised its full-year product revenue guidance to between $525 million and $540 million.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Arcutis Biotherapeutics stock rise?

Arcutis Biotherapeutics stock climbed after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price target, citing rapid commercial expansion for flagship drug Zoryve.

What skin conditions does Zoryve target?

Zoryve is a topical PDE4 inhibitor formulated for large skin-related inflammatory conditions, including atopic dermatitis.

What is Arcutis Biotherapeutics' full-year sales guidance?

Arcutis projected full-year net product sales between $525 million and $540 million, upgraded from its previous forecast of $480 million to $495 million following second-quarter results.